UCB Divests its US Generics Arm to Advent International and Avista Capital Partners for US$1525 M
By Heather Cartwright & Smita Mishra
Pharma Deals Review: Vol 2014 Issue 11 (Table of Contents)
Published: 29 Nov-2014
DOI: 10.3833/pdr.v2014.i11.2079 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
UCB has agreed to divest its US generics drug unit Kremers Urban Pharmaceuticals to Advent International and Avista Capital Partners for US$1525 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS